Tumor multifocality and serum albumin levels can identify groups of patients with hepatocellular carcinoma and portal vein thrombosis having distinct survival outcomes

Basit Öğe Kaydı
dc.authoridDonghia, Rossella/0000-0002-9140-673X
dc.contributor.authorCarr, B., I
dc.contributor.authorGuerra, V
dc.contributor.authorDonghia, R.
dc.contributor.authorYilmaz, S.
dc.date.accessioned2024-08-04T20:50:17Z
dc.date.available2024-08-04T20:50:17Z
dc.date.issued2021
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground: Macroscopic portal vein thrombosis (PVT) is a major poor prognosis factor in patients with hepatocellular carcinoma (HCC), but constitute a heterogeneous group. Aims: To examine blood and tumor parameters of 1667 HCC patients who had PVT to identify factors that could differentiate different survival subsets. Methods: a large HCC database was examined for presence of patients with PVT and analyzed retrospectively for PVT-associated factors and prognosis. Results: A logistic regression model was calculated for presence of PVT. Highest odds ratios were found for tumor multifocality and serum albumin levels, as well as serum alpha-fetoprotein (AFP) and bilirubin levels. A KaplanMeier and Cox model on survival also showed the highest hazard ratios for tumor multifocality and serum albumin. A model was constructed on all 4 possible combinations of tumor focality and serum albumin in PVT patients. The longest survival group had 2 tumor nodules plus serum albumin 3.5 g/dL. Conversely, the shortest survival group had >2 tumor nodules plus serum albumin <3.5 g/dL. These 2 patient groups differed in maximum tumor diameter and levels of serum AFP, AST and bilirubin. Conclusions: Combination low tumor focality and high serum albumin identifies prognostically better PVT patient subgroups that might benefit from aggressive therapies.en_US
dc.description.sponsorshipNIH [CA 82723]en_US
dc.description.sponsorshipThis work was supported in part by NIH grant CA 82723 (B.I.C) .en_US
dc.identifier.doi10.1016/j.amsu.2021.102458
dc.identifier.issn2049-0801
dc.identifier.pmid34141428en_US
dc.identifier.scopus2-s2.0-85107303580en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.1016/j.amsu.2021.102458
dc.identifier.urihttps://hdl.handle.net/11616/99969
dc.identifier.volume66en_US
dc.identifier.wosWOS:000670130100001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Sci Ltden_US
dc.relation.ispartofAnnals of Medicine and Surgeryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHCCen_US
dc.subjectFocalityen_US
dc.subjectAlbuminen_US
dc.subjectSurvivalen_US
dc.titleTumor multifocality and serum albumin levels can identify groups of patients with hepatocellular carcinoma and portal vein thrombosis having distinct survival outcomesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu